Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Aspirin resistance: definition, mechanisms and clinical read-outs.

Patrono C.

J Thromb Haemost. 2003 Aug;1(8):1710-3. Review. No abstract available.

2.

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.

Maree AO, Fitzgerald DJ.

Circulation. 2007 Apr 24;115(16):2196-207. Review. No abstract available.

3.

Aspirin resistance: what, why and when?

Shantsila E, Watson T, Lip GY.

Thromb Res. 2007;119(5):551-4. Epub 2006 Sep 27. Review. No abstract available.

PMID:
17010411
4.

Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness.

Dobaczewski M, Nocun M, Zavodnik I, Ulicna O, Lapshina E, Zavodnik L, Golanski J, Kazmierczak P, Durackova Z, Kostka B, Markuszewski L, Watala C.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):421-8. doi: 10.1097/MBC.0b013e3283049686.

PMID:
18600093
5.

Terms and conditions: semantic complexity and aspirin resistance.

Hennekens CH, Schror K, Weisman S, FitzGerald GA.

Circulation. 2004 Sep 21;110(12):1706-8. Review. No abstract available.

6.

Determinants of the interindividual variability in response to antiplatelet drugs.

Rocca B, Patrono C.

J Thromb Haemost. 2005 Aug;3(8):1597-602. Review.

7.

Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative.

Knoepp SM, Laposata M.

Am J Clin Pathol. 2005 Jun;123 Suppl:S125-32. Review.

PMID:
16100874
8.

Clinical implications of aspirin resistance.

Patel D, Moonis M.

Expert Rev Cardiovasc Ther. 2007 Sep;5(5):969-75. Review.

PMID:
17867925
9.
10.

NSAIDs and cardiovascular risk.

Kotob F, de Leon-Casasola OA, Lema MJ.

Cell Metab. 2005 Dec;2(6):339; author reply 339. No abstract available.

11.

[Therapy with aspirin: a new look at the old problem].

Katkova OV, Laguta PS, Panchenko EP.

Angiol Sosud Khir. 2007;13(2):9-14. Review. Russian.

PMID:
18004254
12.

Aspirin resistance: biological and clinical implications.

Tseeng S, Arora R.

J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):5-12. doi: 10.1177/1074248407310869. Review.

PMID:
18287586
13.

Aspirin resistance.

Szczeklik A, MusiaƂ J, Undas A, Sanak M.

J Thromb Haemost. 2005 Aug;3(8):1655-62. Review.

14.

Aspirin and coronary artery disease.

Maree AO, Fitzgerald DJ.

Thromb Haemost. 2004 Dec;92(6):1175-81. Review.

PMID:
15583721
15.

Clinical implications of prostaglandin and thromboxane A2 formation (1).

Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd.

N Engl J Med. 1988 Sep 15;319(11):689-98. Review. No abstract available.

PMID:
3045550
16.

Aspirin resistance.

Rouvier J, Scazziota A, Altman R.

Circulation. 2002 Dec 10;106(24):e200-1; author reply e200-1. No abstract available.

17.
18.
19.

Aspirin resistance transient laboratory finding or important clinical entity?

Lev EI.

J Am Coll Cardiol. 2009 Feb 24;53(8):678-80. doi: 10.1016/j.jacc.2008.11.018. No abstract available.

20.

Can platelet function tests predict the clinical efficacy of aspirin?

Haubelt H, Anders C, Hellstern P.

Semin Thromb Hemost. 2005;31(4):404-10. Review.

PMID:
16149017

Supplemental Content

Support Center